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OBJECTIVE: To describe the length of stay, cost of 
drug treatment, diagnostic tests and other therapeutic
measures in acute psychotic patients admitted to acute 
in-patient psychiatric units and to analyse the factors
associated with these. METHODS: Retrospective review
of medical records of 200 patients admitted for acute 
psychosis in 8 Spanish hospitals. Description of the length
of stay, cost of drug treatment and diagnostic tests; bivari-
ate and multivariate analysis of factors associated with
length of stay and cost of antipsychotic drug treatment.
RESULTS: The average admission cost ranged between
€2,830.29 and €3,624.95, with a wide variability among
hospitals. Of this cost, 94.3% corresponded to ﬁxed
costs, 3.4% to diagnostic tests and 2.4% to drug 
treatment (84.2% of this latter cost corresponded to
antipsychotic drugs). An age younger than 25 years and
a diagnosis of schizophrenia were associated with longer
hospital stays; longer length of stay, the presence of
aggressiveness/agitation, a diagnosis of schizophrenia, age
younger than 25 years and the use of atypical antipsy-
chotics were associated with higher costs in antipsychotic
drug treatment. CONCLUSIONS: The hospital admis-
sion cost of an acute psychotic episode is mostly depen-
dent on the structural costs derived from in-patient
treatment. The differences in costs seem to be related to
different length of stay schemes used by the various hos-
pitals rather than to the clinical characteristics of patients
or the drugs used.
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OBJECTIVES: To compare antipsychotic medication 
patterns, side-effects and concomitant medication usage
for olanzapine and haloperidol patients in a cross-
sectional analysis of the GEO observational study.
METHODS: GEO is a 2-year prospective naturalistic
combined in- and outpatient observational study in
Germany. 646 adult schizophrenia patients treated with
either olanzapine (N = 416) or haloperidol (N = 230)
were enrolled in the study and quarterly observations on
the disease course, resource consumption and quality of
life are made during the follow-up period. RESULTS:
More olanzapine patients were newly switched to their
current treatment (27% vs. 18% within 2 weeks before
enrolment) or switched more than 2 weeks but less than
3 months before enrolment (19% vs. 12%). Patients
switched within the last 3 months had spent more days
in hospital during the last year than patients treated for
more than 3 months (29 days vs. 15 days). In the 12
months prior to being enrolled in the study, olanzapine
patients had spent more days in hospital due to schizo-
phrenia compared with the haloperidol patients (23 vs.
19 days). Olanzapine patients had lower incidence of
treatment related EPS side-effects (27% vs. 70%),
whereas other treatment side-effects (mainly related to
adipositas and depression) were reported more frequently
for olanzapine patients (29% vs. 9%). A smaller 
proportion of olanzapine patients received concomitant
antipsychotic medication (31.0% vs. 48.7%) and EPS
medication (1.6% vs. 20.5%) compared with haloperidol
patients. The concomitant use of antidepressants (24.8%
vs. 5.4%) and anxiolytics (24.0% vs. 13.4%) were more
common for olanzapine compared with haloperidol
patients. CONCLUSIONS: At time of enrolment in the
GEO observational study, more olanzapine patients were
recently switched to their current treatment, and had
spent more days in hospital. Additional antipsychotic
medication use was more common for haloperidol
patients. Olanzapine patients had fewer treatment 
side-effects and lower usage of concomitant side-effects
medication.
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OBJECTIVES: To compare disease characteristics, living
situations and employment status for schizophrenia
patients treated with olanzapine or haloperidol in a 
cross-sectional analysis of the GEO observational study.
METHODS: GEO is a 2-year prospective naturalistic
